Profund Advisors LLC Has $1.63 Million Position in CG Oncology, Inc. $CGON

Profund Advisors LLC lifted its position in shares of CG Oncology, Inc. (NASDAQ:CGON) by 185.9% during the 4th quarter, Holdings Channel reports. The firm owned 39,319 shares of the company’s stock after purchasing an additional 25,568 shares during the quarter. Profund Advisors LLC’s holdings in CG Oncology were worth $1,633,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of CGON. Whittier Trust Co. of Nevada Inc. acquired a new stake in CG Oncology in the 4th quarter valued at about $27,000. Strengthening Families & Communities LLC acquired a new position in CG Oncology during the third quarter worth approximately $40,000. Comerica Bank increased its position in CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after buying an additional 515 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in CG Oncology by 33.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after buying an additional 972 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in CG Oncology by 159.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after buying an additional 4,288 shares during the period. 26.56% of the stock is owned by institutional investors.

CG Oncology Stock Up 2.3%

Shares of NASDAQ:CGON opened at $64.76 on Thursday. CG Oncology, Inc. has a 12-month low of $23.65 and a 12-month high of $75.50. The business has a 50 day moving average of $67.20 and a 200-day moving average of $54.46. The stock has a market cap of $5.71 billion, a PE ratio of -27.79 and a beta of 0.41.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. Equities research analysts expect that CG Oncology, Inc. will post -2.89 earnings per share for the current year.

Insider Buying and Selling

In other CG Oncology news, Director James Mulay sold 15,600 shares of the stock in a transaction on Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the transaction, the director owned 15,600 shares in the company, valued at $1,138,956. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on CGON. JPMorgan Chase & Co. lifted their target price on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of CG Oncology in a research note on Monday. Wall Street Zen downgraded CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Wedbush lifted their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Finally, Truist Financial reiterated a “buy” rating and issued a $82.00 price objective (up from $77.00) on shares of CG Oncology in a report on Thursday, May 14th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CG Oncology presently has an average rating of “Moderate Buy” and a consensus target price of $81.73.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.